CareDxCDNA
About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
Employees: 643
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
74% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 50
49% more call options, than puts
Call options by funds: $763K | Put options by funds: $512K
0.32% more ownership
Funds ownership: 97.96% [Q3] → 98.28% (+0.32%) [Q4]
2% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 41
5% less funds holding
Funds holding: 215 [Q3] → 205 (-10) [Q4]
30% less capital invested
Capital invested by funds: $1.61B [Q3] → $1.13B (-$483M) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 3 (-2) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Wells Fargo Brandon Couillard 14% 1-year accuracy 3 / 22 met price target | 8%upside $24 | Equal-Weight Upgraded | 15 Jan 2025 |
HC Wainwright & Co. Yi Chen 42% 1-year accuracy 67 / 161 met price target | 17%upside $26 | Neutral Reiterated | 14 Jan 2025 |
Financial journalist opinion
Based on 10 articles about CDNA published over the past 30 days
